Revenue: As of FY2026 Q3, the actual value is USD 0.

EPS: As of FY2026 Q3, the actual value is USD -0.6, missing the estimate of USD -0.435.

EBIT: As of FY2026 Q3, the actual value is USD -5.408 M.

Financial Highlights for the Three Months Ended June 30, 2026

Operating Expenses

Total operating expenses for Edesa Biotech, Inc. increased by $3.6 million to $5.5 million for the three months ended June 30, 2026, compared to $1.9 million for the same period in the prior year. Research and development expenses rose by $3.1 million to $4.0 million, up from $0.9 million, primarily due to increased manufacturing-related activities, preparations for the planned Phase 2 clinical study of EB06, and increased unallocated research costs. General and administrative expenses increased by $0.6 million to $1.6 million, compared to $1.0 million, mainly due to increases in noncash share-based compensation and professional fees.

Other Income

Total other income decreased by approximately $42,000 to $112,000 for the three months ended June 30, 2026, compared to $154,000 in the prior year, primarily due to a decrease in reimbursement funding from the Canadian government’s Strategic Response Fund.

Net Loss

Edesa Biotech, Inc. reported a net loss of -$5.4 million for the quarter ended June 30, 2026, compared to a net loss of -$1.7 million for the quarter ended June 30, 2025.

Financial Highlights for the Nine Months Ended June 30, 2026

Operating Expenses

Total operating expenses increased by $6.8 million to $12.2 million for the nine months ended June 30, 2026, compared to $5.4 million for the same period in the prior year. Research and development expenses increased by $5.4 million to $7.8 million, up from $2.4 million, mainly due to increased manufacturing-related activities, preparations for the planned Phase 2 clinical study of EB06, and increased unallocated research costs. General and administrative expenses increased by $1.3 million to $4.3 million, compared to $3.0 million, mainly due to increases in noncash share-based compensation and professional fees.

Other Income

Total other income decreased by $200,000 to $285,000 for the nine months ended June 30, 2026, compared to $485,000 in the prior year, primarily due to a decrease in reimbursement funding from the Canadian government’s Strategic Response Fund.

Net Loss

Edesa Biotech, Inc. reported a net loss of -$11.9 million for the nine months ended June 30, 2026, compared to a net loss of -$5.0 million for the nine months ended June 30, 2025.

Working Capital and Cash Flow

As of June 30, 2026, Edesa Biotech, Inc. had cash and cash equivalents of $10.3 million and working capital of $6.9 million. Net cash used in operating activities for the nine months ended June 30, 2026, was -$7,186,629, compared to -$5,601,268 for the same period in 2025. Net cash provided by financing activities for the nine months ended June 30, 2026, was $6,793,376, compared to $16,844,415 for the same period in 2025. The net change in cash and cash equivalents was -$459,652 for the nine months ended June 30, 2026, compared to $11,324,370 for the same period in 2025. Cash and cash equivalents at the end of the period, June 30, 2026, totaled $10,332,520, compared to $12,361,690 at June 30, 2025.

Outlook and Guidance

Edesa Biotech, Inc. has completed preparations for its Phase 2 clinical study of EB06 for vitiligo, with patient recruitment expected to commence shortly in Canada and other jurisdictions to follow. The company is continuing to evaluate potential regulatory pathways and advance strategic discussions for its paridiprubart program, following positive exploratory data in ARDS patients with acute kidney injury. Management’s priority is the execution of the EB06 Phase 2 study, alongside supporting regulatory, manufacturing, and business development activities for paridiprubart.